Could Aimmune Therapeutics Inc (NASDAQ:AIMT) Change Direction After More Shorts?

April 17, 2018 - By Harriett Tippett

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) registered an increase of 12.22% in short interest. AIMT’s total short interest was 4.64M shares in April as published by FINRA. Its up 12.22% from 4.13 million shares, reported previously. With 991,900 shares average volume, it will take short sellers 5 days to cover their AIMT’s short positions. The short interest to Aimmune Therapeutics Inc’s float is 16.59%.

The stock increased 5.35% or $1.66 during the last trading session, reaching $32.67. About 409,292 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 29.28% since April 17, 2017 and is uptrending. It has outperformed by 17.73% the S&P500.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.90 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: